You, Ruxu <br/><br/>
Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China.  [electronic resource] 

 -  Cancer management and research  2019 
 - 10239-10248 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1179-1322 
<br/><br/><label>Standard No.: </label>10.2147/CMAR.S219722  doi